Clinical trials: Treatment Resistant Depressive Disorder
Treatment Resistant Depression
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
This Phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmucosal buccal film (VLS-01-BU) in patients with treatment resistant Major…
- Trial name
- NCT06524830
- Testing
- VLS-01-203 BU
- Where
- 48 sites in United States, Australia and 2 more
- Volunteers
- 142 people
- Sponsor
- atai Therapeutics, Inc.
Major Depressive Disorder (MDD)
Accelerated Neuromodulation of Anterior Cingulate Cortex for Depression
The goal of this clinical trial is to test whether an accelerated deep Transcranial Magnetic Stimulation (dTMS) protocol can reduce depressive symptoms in older adults (ages 60-85) with Major Depressive Disorder (MDD) who have…
- Trial name
- NACC-D (NCT07212465)
- Testing
- Active Brainsway H7-Coil Deep TMS System
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Rotman Research Institute at Baycrest
Major Depressive Disorder
Clinical Trial on Efficacy of rTMS to Improve ECT in Treatment-Resistant Depression
It's a prospective, multicentric, randomized, controlled study concerning 56 patients with treatment-resistant depression (TRD).
- Trial name
- STIMAGNECT (NCT02830399)
- Testing
- active rTMS-ECT
- Where
- 3 sites in France
- Volunteers
- 56 people
- Sponsor
- Centre Hospitalier du Rouvray
Treatment- Resistant Bipolar Disorder, Bipolar Disorder
Nitrous TRD Bipolar Depression
Investigators will study approximately 64 patients with Treatment-Resistant Bipolar Depressive Disorder, defined as a failure of at least 1 antidepressants in the current depressive episode and 2 lifetime medication failures.
- Conditions
- Treatment- Resistant Bipolar Disorder, Bipolar Disorder, Bipolar Depressive Disorder
- Trial name
- NCT02757521
- Testing
- Nitrous Oxide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
A Study of Ketamine in Patients With Treatment-resistant Depression
The purpose of this study is to explore the optimal dose frequency of ketamine in patients with treatment-resistant depression (TRD).
- Trial name
- NCT01627782
- Testing
- Ketamine
- Where
- 13 sites in United States
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC
Treatment Resistant Depression
D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression
This is a two-stage experiment; the first stage is an open label trial in which participants receive six intravenous (IV) treatments of ketamine. The second stage includes participants that responded to ketamine (i.e.
- Trial name
- NCT02772211
- Testing
- Ketamine, D-cycloserine
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Sheba Medical Center
Depression - Major Depressive Disorder
Effect of Neurofeedback and TMS
The goal of this clinical trial is to is to learn whether adding EEG neurofeedback (NFB) to repetitive transcranial magnetic stimulation (rTMS) is safe and feasible for adults with major depressive disorder (MDD).
- Trial name
- NCT07892287
- Testing
- Repetitive Transcranial Magnetic Stimulation, Alpha-down EEG Neurofeedback
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder, Suicide
i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial
Approximately four thousand Canadians die by suicide every year, and suicide is the second leading cause of death in youth and young adults (15-34 years).
- Conditions
- Major Depressive Disorder, Suicide, Treatment Resistant Depression
- Trial name
- Ket-CBT (NCT06480500)
- Testing
- Ketamine hydrochloride, i-CBT (Internet-based Cognitive Behavioural Therapy), Midazolam Hydrochloride
- Where
- Canada
- Volunteers
- 76 people
- Sponsor
- University Health Network, Toronto
Late Life Depression (LLD), Depression - Major Depressive Disorder
Accelerated vs. Conventional Theta Burst Stimulation for Late-life Depression
The purpose of this trial is to compare the treatment efficacy (improvement in depressive symptoms) of accelerated TBS protocol (where participants receive multiple TBS treatments daily) to conventional TBS protocol (where…
- Conditions
- Late Life Depression (LLD), Depression - Major Depressive Disorder, Depressive Disorder, Treatment-Resistant, Mood Disorders
- Trial name
- ACT-LLD (NCT06854367)
- Testing
- TBS
- Where
- 2 sites in Canada
- Volunteers
- 280 people
- Sponsor
- Centre for Addiction and Mental Health
Treatment Resistant Depression
Establishing a Dose-response Relationship With Accelerated Transcranial Magnetic Stimulation
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression.
- Trial name
- NCT04243798
- Testing
- Active TBS-DLPFC
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Stanford University
Patients With Resistant Depressive Disorders
Monocentric Pilot Study, for a Randomized, Crossover, Blinded Trial: Comparison of the Therapeutic Efficacy of Low Frequency Repeated Transcranial Magnetic Stimulation on Cortical Area 9 Compared to Brodmann Area 46 in the Treatment of Depressive Disorders.
Repetitive transcranial magnetic stimulation (rTMS) is a new therapeutic tool used in psychiatry. Non-invasive, well tolerated and requiring no premedication, it is performed on an outpatient basis.
- Trial name
- rTMS (NCT03656900)
- Testing
- rTMS BA9/BA46, rTMS BA46/BA9, brain MRI
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Depression
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
The purpose of this study it to evaluate the long-term safety and tolerability of BMS-820836 in patients with depression.
- Trial name
- NCT01361555
- Testing
- BMS-820836
- Where
- 144 sites in United States, Argentina and 10 more
- Volunteers
- 789 people
- Sponsor
- Bristol-Myers Squibb
Major Depressive Disorder, Major Depressive Episode
Glabellar Botulinum Toxin Injections for the Treatment of Geriatric Depression
The effectiveness of glabellar injection of botulinum toxin type A (BTA) in treating depression has not yet been investigated in elderly patients.
- Conditions
- Major Depressive Disorder, Major Depressive Episode, Treatment Resistant Depression
- Trial name
- BOTDEP (NCT03833063)
- Testing
- botulinum toxin A
- Sponsor
- Helse Stavanger HF
Depression
Mifepristone in Refractory Depression
The purpose of the study is to examine the effectiveness of mifepristone treatment in patients with refractory depression. Refractory depression is defined as clinical depression that is unimproved after treatment with at least 2…
- Trial name
- NCT00186056
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Stanford University
Major Depressive Disorder, Treatment Resistant Depression
Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression
We propose a clinical study of medial forebrain bundle DBS as a treatment in 20 patients with treatment refractory depression (TRD).
- Trial name
- NCT02046330
- Testing
- Deep Brain Stimulation Model 3387 Model 3389
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- The University of Texas Health Science Center, Houston
Major Depressive Disorder
Treatment-Resistant Depression Registry
This registry will collect information about patients with treatment-resistant depression (TRD) who are currently in a major depressive episode.
- Trial name
- NCT00320372
- Where
- 55 sites in United States
- Volunteers
- 795 people
- Sponsor
- Cyberonics, Inc.
Major Depression
Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism
Reduction of volume of the hippocampus has been associated with major depression in many studies. It has been suggested that antidepressants may protect against hippocampus volume loss in humans associated with multiple episodes…
- Trial name
- NCT00704860
- Testing
- Open label pharmacotherapy
- Where
- Canada
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University of Ottawa
Treatment Resistant Depression, Major Depressive Disorder
Mechanistic Evaluation of Response in TRD (MERIT)
To evaluate the relapse prevention of AXS-05 relative to placebo in subjects with treatment resistant depression (TRD). This is a randomized, double-blind, placebo-controlled study to evaluate AXS-05 compared to placebo in…
- Trial name
- MERIT (NCT04608396)
- Testing
- AXS-05
- Where
- 20 sites in United States
- Volunteers
- 44 people
- Sponsor
- Axsome Therapeutics, Inc.
Treatment Resistant Depression
Trial of Low Field Magnetic Stimulation Augmentation of Antidepressant Therapy in Treatment-Resistant Depression
This study is looking at the safety and efficacy of low field magnetic stimulation (LFMS) for treating patients with treatment resistant depression who are taking an antidepressant that is not working for them.
- Trial name
- RAPID (NCT01654796)
- Testing
- Low Field Magnetic Stimulation (LFMS)
- Where
- 6 sites in United States
- Volunteers
- 84 people
- Sponsor
- Massachusetts General Hospital
Depression
Effectiveness of Pramipexole for Treatment-Resistant Depression
This study will evaluate the effectiveness of pramipexole (Mirapex) in managing treatment-resistant depression.
- Trial name
- NCT00231959
- Testing
- Pramipexole (Mirapex)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Massachusetts General Hospital